Recombinant Lucihormetica grossei Periviscerokinin-3

What is Periviscerokinin-3 from Lucihormetica grossei and what is its sequence?

Periviscerokinin-3 is one of the CAPA family neuropeptides isolated from Lucihormetica grossei (Mega Glowspot Cockroach), a cockroach species native to Venezuela. Based on peptide sequence analysis, it appears to be the sequence G-SSG-MIPFPRVa, which shows the characteristic C-terminal PRVa motif common to periviscerokinin peptides . This peptide is part of a conserved group of neuropeptides that typically function in regulating physiological processes such as diuresis and muscle contraction in insects.

How does L. grossei Periviscerokinin-3 compare to similar peptides from related species?

The sequence alignment data reveals high conservation of Periviscerokinin-3 among Lucihormetica species:

This high sequence conservation within the Blaberidae family suggests critical functional importance and evolutionary pressure to maintain this specific structure . The minor variations in sequence between genera may reflect adaptations to specific ecological niches or physiological requirements.

Which expression systems are most effective for recombinant production of L. grossei Periviscerokinin-3?

For recombinant production of short peptides like Periviscerokinin-3 (11 amino acids), several expression systems can be employed with varying advantages:

The methodology should be selected based on specific research requirements, particularly whether C-terminal amidation (indicated by the "a" in the sequence) needs to be authentically reproduced.

What fusion tag strategies optimize the expression and purification of recombinant Periviscerokinin-3?

For Periviscerokinin-3, a SUMO-fusion strategy typically yields the best balance between expression level and the ability to obtain the native peptide after cleavage without additional amino acids.

What is the optimal purification strategy for obtaining high-purity recombinant Periviscerokinin-3?

A multi-stage purification approach is recommended:

• Initial Capture:

  • Immobilized metal affinity chromatography (IMAC) for His-tagged constructs

  • Glutathione affinity chromatography for GST-fusion proteins

• Tag Removal:

  • Site-specific protease cleavage (TEV, SUMO, or PreScission protease)

  • Reverse-IMAC to remove cleaved tag and uncleaved fusion protein

• Polishing Steps:

  • Ion exchange chromatography (IEX) at pH 8.0 (peptide theoretical pI ≈ 9.5)

  • Size exclusion chromatography (SEC) using Superdex Peptide column

  • Reverse-phase HPLC using C18 column with acetonitrile gradient

• Quality Control:

  • Mass spectrometry to confirm exact mass (1169.6 Da for G-SSG-MIPFPRVa)

  • Circular dichroism to assess secondary structure

  • Analytical HPLC for purity assessment (target >95%)

What analytical techniques best characterize recombinant Periviscerokinin-3 structure and modifications?

For monitoring C-terminal amidation specifically, a combination of high-resolution mass spectrometry and tandem MS/MS with electron transfer dissociation is most effective.

What methodologies effectively validate the biological activity of recombinant Periviscerokinin-3?

Functional validation requires expression of the appropriate G protein-coupled receptor in heterologous systems, typically HEK293 or CHO-K1 cells, followed by dose-response studies comparing the recombinant peptide to synthetic standards.

How can structure-activity relationship studies enhance understanding of Periviscerokinin-3 function?

Structure-activity relationship (SAR) studies for Periviscerokinin-3 should systematically modify the peptide sequence to determine:

• Essential residues: Alanine scanning mutagenesis of each position

• C-terminal amidation: Comparison of amidated vs. free acid forms

• N-terminal modifications: Truncation analysis and acetylation effects

• Core region flexibility: Proline substitutions in the MIPF motif

• Secondary structure propensity: Helix-promoting substitutions

These studies should employ both computational modeling (molecular dynamics) and experimental validation through receptor binding and activation assays to develop a comprehensive functional map of the peptide.

How can comparative genomics enhance understanding of Periviscerokinin-3 evolution and function?

A systematic comparative genomics approach should include:

• Identification of CAPA precursor genes across Dictyoptera species

• Analysis of conserved regulatory elements controlling expression

• Examination of gene duplication events within the Blaberidae family

• Correlation of sequence variations with species-specific physiological adaptations

• Reconstruction of the evolutionary history of periviscerokinin peptides

This approach has revealed that the Lucihormetica genus maintains highly conserved CAPA peptide sequences compared to other cockroach families, suggesting specific functional constraints on these neuropeptides .

What challenges exist in studying receptor-ligand interactions of Periviscerokinin-3, and how can they be addressed?

Key challenges and solutions include:

A combination of these approaches provides a comprehensive picture of how Periviscerokinin-3 engages its receptor and initiates downstream signaling cascades.

What are common challenges in recombinant Periviscerokinin-3 production and how can they be resolved?

Systematic optimization of these parameters typically resolves most production issues encountered with recombinant Periviscerokinin-3.

How can researchers effectively address stability challenges with Periviscerokinin-3 in experimental systems?

To enhance peptide stability during experimentation:

• Storage conditions:

  • Lyophilized powder at -20°C for long-term storage

  • Small aliquots in 20% acetonitrile/0.1% TFA at -80°C

  • Avoid repeated freeze-thaw cycles

• Chemical stabilization approaches:

  • N-terminal acetylation to prevent aminopeptidase degradation

  • D-amino acid substitutions at proteolytically sensitive sites

  • PEGylation for extended in vivo half-life

  • Cyclization strategies for enhanced stability

• Formulation considerations:

  • Addition of carrier proteins (0.1% BSA) for dilute solutions

  • Use of protease inhibitor cocktails in biological assays

  • pH optimization (typically pH 5.5-6.5 for maximal stability)

• Monitoring approach:

  • Regular analytical HPLC monitoring of stock solutions

  • MS verification before critical experiments

  • Inclusion of stability controls in functional assays